Company: PHAT
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034183
Chunk: 260

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 260
---
ization

    795

    575

    Stock-based compensation

    24,047

    45,025

    Issuance of PIK interest debt

    3,775

    3,583

    Accrued interest on revenue interest financing liability

    46,111

    24,727

    Amortization of debt discount

    2,192

    1,877

    Inventory reserve

    836

    —

    Other

    5,098

    1,869

    Changes in operating assets and liabilities:

    Prepaid expenses and other current assets

    (7,672
    )

    (8,067
    )

    Accounts receivable, net

    (37,160
    )

    (1,637
    )

    Accounts payable and accrued expenses

    34,936

    6,410

    Accrued interest

    565

    292

    Operating right-of-use assets and lease liabilities

    175

    194

    Inventory

    (6,142
    )

    (9,442
    )

    Other long-term assets

    —

    (1,394
    )

    Net cash used in operating activities

    (266,770
    )

    (137,580
    )

    Cash flows from investing activities

    Cash paid for property and equipment

    (135
    )

    (1,634
    )

    Net cash used in investing activities

    (135
    )

    (1,634
    )

    Cash flows from financing activities

    Proceeds from issuance of common stock from exercise of stock options

    1,599

    124

    Net proceeds from issuance of debt

    59,400

    39,318

    Net proceeds from underwritten public offering

    121,775

    141,390

    Net proceeds from revenue interest financing transaction

    —

    172,675

    Net proceeds from issuance of common stock under ATM facility

    —

    14,073

    Net cash provided by financing activities

    182,774

    367,580

    Net (decrease) increase in cash and cash equivalents and restricted cash

    (84,131
    )

    228,366

    Cash and cash equivalents and restricted cash – beginning of period

    384,256